Suda Pharmaceuticals Ltdの株式の価格
Suda Pharmaceuticals Ltdの株式の価格 は何ですか。
Suda Pharmaceuticals Ltdの株式の価格 は0.01です。
株式の価格 の定義は何ですか。
1株当たりキャッシュは、会社の手持ち現金を会社の発行済株式で割ったものです。
Cash per share, sometimes called the cash share ratio, is the total cash per share. Cash on hand is reported on the balance sheet. Cash per share is calculated by dividing cash on hand by the total number of shares. Cash per share is the percentage of a firm's share price that is immediately accessible for spending. Cash per share consists of cash and short-term investments. It is money that a firm has on hand and does not come from borrowing or financing activities.
When a firm has a high cash per share, significant percentage of its assets is in a very liquid form. This can indicate economic uncertainty and unwillingness to invest given the current economic climate. High levels of cash per share can indicate that a firm is performing well and is able to reinvest in itself but high cash per share does not always indicate overall financial strength.
ASXのセクタHealth Careにおける株式の価格 の企業と比べるSuda Pharmaceuticals Ltd
Suda Pharmaceuticals Ltdは何をしますか。
Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.
Suda Pharmaceuticals Ltdと類似の株式の価格
- Air Industriesの株式の価格 は0.01です。
- IDG Investmentの株式の価格 は0.01です。
- Surgalignの株式の価格 は0.01です。
- Global Petroleumの株式の価格 は0.01です。
- Enviro Internationalの株式の価格 は0.01です。
- Yestar Healthcareの株式の価格 は0.01です。
- Suda Pharmaceuticals Ltdの株式の価格 は0.01です。
- TANSH Global Food Co., Ltdの株式の価格 は0.01です。
- Century Sage Scientificの株式の価格 は0.01です。
- Sino Oil and Gasの株式の価格 は0.01です。
- Chong Sing FinTechの株式の価格 は0.01です。
- China Brilliant Globalの株式の価格 は0.01です。
- 3P Learningの株式の価格 は0.01です。